Intranasal delivery of insulin and GLP-1 peptides could eliminate injections for diabetics, offering higher bioavailability and better patient compliance through various formulation strategies.
Needle-free peptide deliveryIntranasal routes could replace painful injections while improving drug absorption and patient compliance for insulin and GLP-1 therapies
What the researchers found
Intranasal delivery of insulin and glucagon-like peptides demonstrates improved therapeutic levels and patient compliance, with drugs transported through epithelial tight junctions via the paracellular route.
Why it matters
Needle-free delivery of peptide drugs like insulin and GLP-1 agonists could transform daily diabetes management, improving quality of life and treatment adherence for hundreds of millions of patients worldwide.
The numbers in context
Strategies: polymers, particulate systems, peptide complexation, glucose-responsive systems; paracellular transport through epithelial tight junctions
How the study worked
Narrative review of published literature covering intranasal antidiabetic formulation strategies, absorption mechanisms, challenges, and emerging technologies like glucose-responsive delivery systems.
Who was studied
Review of preclinical and formulation research on intranasal antidiabetic drug delivery
What this study cannot tell us
Review with mostly preclinical data. Nasal delivery faces real-world challenges including enzyme degradation, mucociliary clearance, limited nasal cavity volume, and potential irritation. Very few products have reached clinical trials.
How to read the evidence
Not applicable (narrative review). Most evidence comes from preclinical formulation studies with limited clinical trial data.
When this study was published
Published in 2021. Nasal peptide delivery research has continued advancing with several formulations now in clinical development.
The bigger picture
The push for needle-free peptide delivery is a major trend in pharmaceutical research. Nasal spray insulin and GLP-1 formulations could make peptide therapies accessible to more patients, especially those who avoid or struggle with injections.
Questions still open
- Can glucose-responsive nasal delivery systems achieve the precision needed for safe insulin dosing?
- How do intranasal GLP-1 peptides compare to subcutaneous injection in terms of efficacy and duration?
- Will nasal peptide formulations be cost-competitive with existing injection-based treatments?
Common questions
Could insulin ever be taken as a nasal spray instead of injection?
What are the main challenges with nasal peptide delivery?
Read the original research
Strategies for the delivery of antidiabetic drugs via intranasal route.
International journal of pharmaceutics, 608, 121068
Citation
Dholakia, Jheel; Prabhakar, Bala; Shende, Pravin. (2021). Strategies for the delivery of antidiabetic drugs via intranasal route.. International journal of pharmaceutics, 608, 121068. https://doi.org/10.1016/j.ijpharm.2021.121068